"I believe in the supremacy of the Feuerstein-Ratain (F-R) Rule, therefore, the Celator phase III study will fail. Celator's market cap of $65 million is deep inside the sub-$300 million market-cap dead zone from which phase III cancer drug trials cannot escape, per the F-R Rule."
Adam Feuerstein
Company got bought 1.5 billions by JAZZ a few weeks after that statement. Thanks for the good laugh, we are just returning the favour.